ET
RPRX icon

Entropy Technologies’s Royalty Pharma RPRX Stock Holding History

Entropy Technologies’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.3M Buy
58,767
+40,142
+216% +$2.09M 0.13% 228
2026
Q1 		$893K Sell
18,625
-70,027
-79% -$3.07M 0.04% 440
2025
Q4 		$3.43M Buy
88,652
+55,994
+171% +$2.14M 0.19% 154
2025
Q3 		$1.15M Sell
32,658
-22,679
-41% -$821K 0.09% 306
2025
Q2 		$1.99M Buy
+55,337
New +$1.83M 0.16% 184

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Entropy Technologies's RPRX Position: Q2 2026 in Review

Entropy Technologies increased its Royalty Pharma (RPRX) stake by 216% in Q2 2026, buying an estimated $2.09M and bringing the position to 58,767 shares worth $3.3M. The position accounts for 0.13% of the portfolio, ranked #228.

Entropy Technologies first reported a position in RPRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $3.43M in Q4 2025. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Entropy Technologies held 58,767 shares of Royalty Pharma worth $3.3M as of Q2 2026.
  • Entropy Technologies bought 40,142 Royalty Pharma shares in Q2 2026, an estimated $2.09M.
  • Royalty Pharma made up 0.13% of Entropy Technologies's portfolio in Q2 2026, its #228 holding.
  • Entropy Technologies first reported a position in Royalty Pharma in Q2 2025 and has held it in 5 quarters since.
  • Entropy Technologies's Royalty Pharma position peaked at $3.43M in Q4 2025.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Entropy Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.